Verve Therapeutics, Inc. (VERV)
Largest Insider Buys in Sector
VERV Stock Price History Chart
VERV Stock Performance
About Verve Therapeutics, Inc.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a …
Insider Activity of Verve Therapeutics, Inc.
Over the last 12 months, insiders at Verve Therapeutics, Inc. have bought $18.48M and sold $18,819 worth of Verve Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Verve Therapeutics, Inc. have bought $51.11M and sold $23.8M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Yeshwant Krishna () — $18M. Ashe Andrew D. (See Remarks) — $475,760.
The last purchase of 76,000 shares for transaction amount of $475,760 was made by Ashe Andrew D. (See Remarks) on 2024‑05‑14.
List of Insider Buy and Sell Transactions, Verve Therapeutics, Inc.
| 2024-05-14 | See Remarks | 76,000 0.0972% | $6.26 | $475,760 | -13.00% | |||
| 2024-04-02 | Sale | Chief Administrative Officer | 1,514 0.0019% | $8.24 | $12,475 | -32.57% | ||
| 2023-12-01 | 1.8M 2.4091% | $10.00 | $18M | -41.61% | ||||
| 2023-11-29 | Sale | Chief Financial Officer | 554 0.0009% | $11.45 | $6,343 | -38.66% | ||
| 2022-12-01 | Sale | CSO & CMO | 865 0.005% | $22.95 | $19,852 | -25.32% | ||
| 2022-11-29 | Sale | Chief Financial Officer | 554 0.0032% | $22.10 | $12,243 | -21.87% | ||
| 2022-11-04 | Sale | director | 48,583 0.2725% | $31.14 | $1.51M | -43.27% | ||
| 2022-11-04 | Sale | director | 194,332 1.0902% | $31.14 | $6.05M | -43.27% | ||
| 2022-11-03 | Sale | director | 49,568 0.2835% | $32.79 | $1.63M | -44.93% | ||
| 2022-11-03 | Sale | director | 71,847 0.4091% | $32.65 | $2.35M | -44.93% | ||
| 2022-11-03 | Sale | director | 99,137 0.567% | $32.79 | $3.25M | -44.93% | ||
| 2022-11-02 | Sale | director | 28,652 0.1679% | $35.94 | $1.03M | -48.38% | ||
| 2022-11-02 | Sale | director | 38,001 0.2209% | $35.66 | $1.35M | -48.38% | ||
| 2022-11-02 | Sale | director | 48,373 0.2822% | $35.79 | $1.73M | -48.38% | ||
| 2022-11-01 | Sale | director | 31,963 0.1819% | $36.79 | $1.18M | -50.88% | ||
| 2022-11-01 | Sale | director | 63,926 0.3638% | $36.79 | $2.35M | -50.88% | ||
| 2022-10-31 | Sale | director | 53,696 0.3102% | $38.64 | $2.07M | -52.36% | ||
| 2022-10-31 | Sale | director | 107,305 0.6199% | $38.64 | $4.15M | -52.36% | ||
| 2022-10-28 | Sale | CSO & CMO | 10,000 0.0553% | $39.90 | $399,000 | -55.82% | ||
| 2022-10-03 | Sale | Chief Executive Officer | 50,000 0.2839% | $33.65 | $1.68M |
Insider Historical Profitability
| Yeshwant Krishna | 1800000 2.127% | $6.38 | 1 | 5 | ||
| Ashe Andrew D. | See Remarks | 342509 0.4047% | $6.38 | 2 | 0 | <0.0001% |
| Casdin Partners Master Fund, L.P. | 10 percent owner | 2417596 2.8569% | $6.38 | 1 | 0 | <0.0001% |
| Redmile Group, LLC | 10 percent owner | 1936530 2.2884% | $6.38 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 984224 1.163% | $6.38 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Alphabet | $164M | 14.71 | 12.35M | 0% | +$0 | 1.34 | |
| The Vanguard Group | $84.08M | 7.54 | 6.33M | +15.71% | +$11.41M | <0.01 | |
| ARK Investment Management LLC | $80.22M | 7.19 | 6.04M | -14.02% | -$13.08M | 0.28 | |
| BlackRock | $71.36M | 6.4 | 5.37M | +21.14% | +$12.45M | <0.01 | |
| State Street | $67.69M | 6.07 | 5.1M | +31.83% | +$16.34M | <0.01 |